相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。A gp130-Src-YAP module links inflammation to epithelial regeneration
Koji Taniguchi et al.
NATURE (2015)
The Hippo effector YAP promotes resistance to RAF- and MEK-targeted cancer therapies
Luping Lin et al.
NATURE GENETICS (2015)
EGFR inhibition evokes innate drug resistance in lung cancer cells by preventing Akt activity and thus inactivating Ets-1 function
Janyaporn Phuchareon et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2015)
NF-κB-Activating Complex Engaged in Response to EGFR Oncogene Inhibition Drives Tumor Cell Survival and Residual Disease in Lung Cancer
Collin M. Blakely et al.
CELL REPORTS (2015)
Drug Resistance via Feedback Activation of Stat3 in Oncogene-Addicted Cancer Cells
Ho-June Lee et al.
CANCER CELL (2014)
TPCA-1 Is a Direct Dual Inhibitor of STAT3 and NF-κB and Regresses Mutant EGFR-Associated Human Non-Small Cell Lung Cancers
Jing Nan et al.
MOLECULAR CANCER THERAPEUTICS (2014)
Genetics and biomarkers in personalisation of lung cancer treatment
Rafael Rosell et al.
LANCET (2013)
β-Catenin-Driven Cancers Require a YAP1 Transcriptional Complex for Survival and Tumorigenesis
Joseph Rosenbluh et al.
CELL (2012)
Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial
Rafael Rosell et al.
LANCET ONCOLOGY (2012)
MET-Independent Lung Cancer Cells Evading EGFR Kinase Inhibitors Are Therapeutically Susceptible to BH3 Mimetic Agents
Weiwen Fan et al.
CANCER RESEARCH (2011)
Pretreatment EGFR T790M Mutation and BRCA1 mRNA Expression in Erlotinib-Treated Advanced Non-Small-Cell Lung Cancer Patients with EGFR Mutations
Rafael Rosell et al.
CLINICAL CANCER RESEARCH (2011)
FAS and NF-κB signalling modulate dependence of lung cancers on mutant EGFR
Trever G. Bivona et al.
NATURE (2011)
Impaired SHP2-Mediated Extracellular Signal-Regulated Kinase Activation Contributes to Gefitinib Sensitivity of Lung Cancer Cells with Epidermal Growth Factor Receptor-Activating Mutations
Matthew J. Lazzara et al.
CANCER RESEARCH (2010)
Drug Combination Studies and Their Synergy Quantification Using the Chou-Talalay Method
Ting-Chao Chou
CANCER RESEARCH (2010)
Enhanced Sensitivity of Pancreatic Cancer Cells to Concurrent Inhibition of Aberrant Signal Transducer and Activator of Transcription 3 and Epidermal Growth Factor Receptor or Src
Soumya Jaganathan et al.
JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS (2010)
Screening for Epidermal Growth Factor Receptor Mutations in Lung Cancer.
Rafael Rosell et al.
NEW ENGLAND JOURNAL OF MEDICINE (2009)
Roles of unphosphorylated STATs in signaling
Jinbo Yang et al.
CELL RESEARCH (2008)
Signaling networks assembled by oncogenic EGFR and c-Met
Ailan Guo et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2008)
Mutations in the EGFR kinase domain mediate STAT3 activation via IL-6 production in human lung adenocarcinomas
Sizhi Paul Gao et al.
JOURNAL OF CLINICAL INVESTIGATION (2007)
Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways
R Sordella et al.
SCIENCE (2004)
分享论文
